Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide in multiple myeloma.

P Richardson1, T Hideshima, K Anderson

  • 1Jerome Lipper Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. paul-richardson@dfci.harvard.edu

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|June 6, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Neurology·2006
Same author

Liming poultry manures to decrease soluble phosphorus and suppress the bacteria population.

Journal of environmental quality·2006
Same author

Evaluation of a new effect-site controlled, patient-maintained sedation system in dental patients.

Anaesthesia·2006
Same author

Cardiovascular changes after induction of anaesthesia.

Anaesthesia·2006
Same author

Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside.

Leukemia·2005
Same author

Penetration of ceftiofur into sterile vs. Mannheimia haemolytica-infected tissue chambers in beef calves after subcutaneous administration of ceftiofur crystalline free acid sterile suspension in the ear pinna.

Journal of veterinary pharmacology and therapeutics·2005

Thalidomide, once withdrawn due to teratogenicity, now shows anti-angiogenic and immunomodulatory effects. It is an effective oral treatment for multiple myeloma and other conditions, with ongoing research into its full therapeutic potential.

Area of Science:

  • Pharmacology
  • Immunology
  • Oncology

Background:

  • Thalidomide, withdrawn in 1962 due to severe teratogenicity, possesses anti-angiogenic and immunomodulatory properties.
  • It inhibits Tumor Necrosis Factor alpha (TNF alpha), contributing to its therapeutic effects.

Purpose of the Study:

  • To review the re-emergence and current applications of thalidomide in clinical practice.
  • To highlight its efficacy in managing conditions like erythema nodosum leprosum and multiple myeloma.
  • To discuss the ongoing research into thalidomide's mechanism of action and therapeutic role in newly diagnosed multiple myeloma.

Main Methods:

  • Review of preclinical studies investigating thalidomide's mechanism of action in multiple myeloma.
  • Analysis of clinical trial data evaluating thalidomide as a single agent and in combination therapies.

Related Experiment Videos

  • Examination of its FDA-approved indications and emerging therapeutic uses.

    • Main Results:

    • Thalidomide has demonstrated efficacy in managing erythema nodosum leprosum (FDA-approved in 1998).
    • Clinical trials confirm thalidomide's benefit in relapsed and refractory multiple myeloma.
    • Preclinical studies have provided significant insights into its mechanism of action, particularly in multiple myeloma.

    Conclusions:

    • Thalidomide has re-established itself as a valuable oral therapeutic agent for specific disease states.
    • It is a crucial treatment option for multiple myeloma, with ongoing studies exploring its use in newly diagnosed patients.
    • Despite an incompletely understood mechanism, thalidomide's clinical benefits are well-established in various malignancies and inflammatory conditions.